melatonin has been researched along with Depressive Disorder, Major in 90 studies
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome." | 9.30 | The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial. ( Andersen, LJ; Andersen, UO; Gögenur, I; Grummedal, O; Hansen, CH; Hansen, JR; Isbrand, A; Madsen, MT; Simonsen, E; Taskiran, M; Zahid, JA, 2019) |
| " A wide array of biochemical processes underlie MDD presentations and their shift to a recurrent, neuroprogressive course, including: increased immune-inflammation, tryptophan catabolites (TRYCATs), mitochondrial dysfunction, aryl hydrocarbonn receptor activation, and oxidative and nitrosative stress (O&NS), as well as decreased sirtuins and melatonergic pathway activity." | 8.98 | Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition. ( Anderson, G, 2018) |
| "Melatonin, which plays an important role for regulation of circadian rhythms and the sleep/wake cycle has been linked to the pathophysiology of major depressive and bipolar disorder." | 7.83 | Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. ( Bumb, JM; Enning, F; Findeisen, P; Leweke, FM; Mueller, JK; Noelte, I; Rohleder, C; Schwarz, E; van der List, T, 2016) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 7.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD)." | 7.74 | The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. ( Akpinar, Z; Gökbel, H; Okudan, N; Tokgöz, S; Uğuz, F; Yilmaz, G, 2008) |
| "Melatonin treatment significantly abolished the effects of LPS, as demonstrated by improved depressive-like behaviors, normalized autophagy-related gene expression, and reduced levels of cytokines." | 5.56 | Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation. ( Ali Shah, F; Ali, T; Hao, Q; Li, S; Li, W; Liu, G; Liu, Z; Murtaza, I; Rahman, SU; Yang, X; Zhang, Z, 2020) |
| "Melatonin showed no prophylactic antidepressant effect following acute coronary syndrome." | 5.30 | The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial. ( Andersen, LJ; Andersen, UO; Gögenur, I; Grummedal, O; Hansen, CH; Hansen, JR; Isbrand, A; Madsen, MT; Simonsen, E; Taskiran, M; Zahid, JA, 2019) |
| " A wide array of biochemical processes underlie MDD presentations and their shift to a recurrent, neuroprogressive course, including: increased immune-inflammation, tryptophan catabolites (TRYCATs), mitochondrial dysfunction, aryl hydrocarbonn receptor activation, and oxidative and nitrosative stress (O&NS), as well as decreased sirtuins and melatonergic pathway activity." | 4.98 | Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition. ( Anderson, G, 2018) |
| "Melatonin and melatonin agonists offer novel treatments for sleep and mood disorders, particularly where circadian misalignment is also present." | 3.91 | Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep and Mood. ( Alston, M; Cain, SW; Rajaratnam, SMW, 2019) |
| "Melatonin, which plays an important role for regulation of circadian rhythms and the sleep/wake cycle has been linked to the pathophysiology of major depressive and bipolar disorder." | 3.83 | Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. ( Bumb, JM; Enning, F; Findeisen, P; Leweke, FM; Mueller, JK; Noelte, I; Rohleder, C; Schwarz, E; van der List, T, 2016) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 3.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "In order to investigate melatonin receptors in the SCN during depression, and their relationship to the major neuropeptides in the SCN, vasopressin (AVP) and vasoactive intestinal peptide (VIP), we studied the SCN in 14 depressed patients (five major depression and nine bipolar disorder) and 14 matched controls by immunocytochemistry." | 3.79 | Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. ( Ai-Min, B; Jockers, R; Scheer, FA; Swaab, DF; Ursinus, J; van Heerikhuize, J; Wu, YH; Zhou, JN, 2013) |
| "The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD)." | 3.74 | The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. ( Akpinar, Z; Gökbel, H; Okudan, N; Tokgöz, S; Uğuz, F; Yilmaz, G, 2008) |
| "We studied mood disorders and urinary melatonin excretion in 382 postmenopausal women." | 3.71 | Depression and endogenous melatonin in postmenopausal women. ( Assmus, JD; Elliott, JA; Klauber, MR; Kripke, DF; Langer, RD; Rex, KM; Tuunainen, A, 2002) |
| "In total, 36 patients with major depressive disorder (MDD) were enrolled for 4-weeks medication and 6-weeks follow-up." | 3.11 | Sini powder with paroxetine ameliorates major depressive disorder by modulating circadian rhythm: A randomized, double-blind, placebo-controlled trial. ( Bai, R; Chen, J; He, X; Hui, Z; Li, L; Li, S; Li, Z; Liu, R; Shen, Y; Xie, X; Yao, Z; Zhang, R; Zhang, S; Zhang, X, 2022) |
| " No withdrawal was observed due to the drugs' adverse effects." | 2.94 | Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial. ( Abbasinazari, M; Badri, T; Ghassab-Sahebkar, A; Keshvari, N; Qobadighadikolaei, R; Sarraf, N, 2020) |
| "Thirty adults with major depressive disorder received 8 weeks of fluoxetine 20-40 mgs and were randomized to 8h TIB or 6h TIB for the first 2 weeks." | 2.84 | Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation. ( Armitage, R; Bertram, H; Burgess, HJ; Dopp, R; Hoffmann, R; Huntley, ED; Mooney, A; Swanson, LM; Todd Arnedt, J; Zollars, J, 2017) |
| "Melatonin is a hypnotic and synchronizes circadian rhythms." | 2.75 | A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. ( Blizard, R; Buszewicz, MJ; Osborne, D; Raven, PW; Serfaty, MA, 2010) |
| "Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a 24-week, randomized, double-blind treatment period." | 2.74 | Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. ( Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F, 2009) |
| "Melatonin rhythms were similar between depressed patients and matched healthy controls." | 2.73 | Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder. ( Bao, AM; Liu, YJ; Tan, ZL; Zhao, GQ; Zhou, JN, 2007) |
| "Ten pregnant women with DSM-IV major depressive disorder were randomly assigned from April 2000 to January 2002 to a 5-week clinical trial with either a 7000 lux (active) or 500 lux (placebo) light box." | 2.71 | Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. ( Epperson, CN; Hanusa, BH; Oren, DA; Peindl, KS; Terman, JS; Terman, M; Wisner, KL, 2004) |
| "Late Wake Treatment (LWT), sleep deprivation for the last half of one night, is associated with rapid mood improvement which has been sustained by light treatment." | 2.71 | Bright green light treatment of depression for older adults [ISRCTN69400161]. ( Grandner, MA; Knickerbocker, NC; Kripke, DF; Loving, RT, 2005) |
| "Paroxetine was used as the study validator." | 2.70 | Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. ( D'haenen, H; Hale, A; Lôo, H, 2002) |
| "Melatonin treatment significantly decreased depression ratings compared to placebo." | 2.69 | Melatonin treatment of winter depression: a pilot study. ( Bauer, VK; Cutler, NL; Lewy, AJ; Sack, RL, 1998) |
| "Major depressive disorder is a complex clinical entity, including different molecular mechanisms and neurological processes." | 2.55 | The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect. ( Filipek, B; Jakubczyk, M; Lustyk, K; Młyniec, K; Podkowa, A; Podkowa, K; Pytka, K; Sapa, J; Żmudzka, E, 2017) |
| "Insomnia is associated with impaired quality of life." | 2.49 | Treatment of resistant insomnia and major depression. ( Acciavatti, T; Cinosi, E; Cornelio, M; De Risio, L; Dezi, S; Di Giannantonio, M; Di Iorio, G; Marini, S; Martinotti, G; Vellante, F, 2013) |
| "Melatonin treatment significantly abolished the effects of LPS, as demonstrated by improved depressive-like behaviors, normalized autophagy-related gene expression, and reduced levels of cytokines." | 1.56 | Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation. ( Ali Shah, F; Ali, T; Hao, Q; Li, S; Li, W; Liu, G; Liu, Z; Murtaza, I; Rahman, SU; Yang, X; Zhang, Z, 2020) |
| "Seasonal affective disorder is defined as recurrent episodes of major depression, mania, or hypomania with seasonal onset and remission." | 1.46 | Secondary to excessive melatonin synthesis, the consumption of tryptophan from outside the blood-brain barrier and melatonin over-signaling in the pars tuberalis may be central to the pathophysiology of winter depression. ( Alves, RC; Pereira, JC; Pradella Hallinan, M, 2017) |
| "Melatonin excretion has been considered a physiological index for noradrenergic function, which in some studies were found to be altered than depressed patients." | 1.33 | Melatonin levels in drug-free patients with major depression from the southern hemisphere. ( Carvalho, LA; Gorenstein, C; Markus, RP; Moreno, RA, 2006) |
| " The greatest decrease in insomnia occurred during the last 2 weeks of the study, following the increase in dosage to 10 mg per day of SR-melatonin." | 1.31 | Use of slow-release melatonin in treatment-resistant depression. ( Brown, GM; Dalton, EJ; Kennedy, SH; Levitan, RD; Rotondi, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.33) | 18.2507 |
| 2000's | 27 (30.00) | 29.6817 |
| 2010's | 52 (57.78) | 24.3611 |
| 2020's | 8 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Naveed, M | 1 |
| Li, LD | 1 |
| Sheng, G | 1 |
| Du, ZW | 1 |
| Zhou, YP | 1 |
| Nan, S | 1 |
| Zhu, MY | 1 |
| Zhang, J | 1 |
| Zhou, QG | 1 |
| He, X | 1 |
| Zhang, R | 1 |
| Li, Z | 1 |
| Yao, Z | 1 |
| Xie, X | 1 |
| Bai, R | 1 |
| Li, L | 1 |
| Zhang, X | 1 |
| Zhang, S | 1 |
| Shen, Y | 1 |
| Li, S | 2 |
| Hui, Z | 1 |
| Liu, R | 1 |
| Chen, J | 1 |
| Wilson, JB | 1 |
| Epstein, M | 1 |
| Lopez, B | 1 |
| Brown, AK | 1 |
| Lutfy, K | 1 |
| Friedman, TC | 1 |
| Madsen, MT | 1 |
| Zahid, JA | 1 |
| Hansen, CH | 1 |
| Grummedal, O | 1 |
| Hansen, JR | 1 |
| Isbrand, A | 1 |
| Andersen, UO | 1 |
| Andersen, LJ | 1 |
| Taskiran, M | 1 |
| Simonsen, E | 1 |
| Gögenur, I | 1 |
| Hong, W | 1 |
| Zhang, Q | 1 |
| Sarraf, N | 1 |
| Badri, T | 1 |
| Keshvari, N | 1 |
| Ghassab-Sahebkar, A | 1 |
| Qobadighadikolaei, R | 1 |
| Abbasinazari, M | 1 |
| Ali, T | 1 |
| Rahman, SU | 1 |
| Hao, Q | 1 |
| Li, W | 1 |
| Liu, Z | 1 |
| Ali Shah, F | 1 |
| Murtaza, I | 1 |
| Zhang, Z | 1 |
| Yang, X | 1 |
| Liu, G | 1 |
| Krystal, AD | 1 |
| Mittoux, A | 1 |
| Lindsten, A | 1 |
| Baker, RA | 1 |
| Hester, L | 1 |
| Dang, D | 1 |
| Barker, CJ | 1 |
| Heath, M | 1 |
| Mesiya, S | 1 |
| Tienabeso, T | 1 |
| Watson, K | 1 |
| Oishi, A | 1 |
| Gbahou, F | 1 |
| Jockers, R | 2 |
| Pytka, K | 1 |
| Młyniec, K | 1 |
| Podkowa, K | 1 |
| Podkowa, A | 1 |
| Jakubczyk, M | 1 |
| Żmudzka, E | 1 |
| Lustyk, K | 1 |
| Sapa, J | 1 |
| Filipek, B | 1 |
| Anderson, G | 1 |
| Allega, OR | 2 |
| Leng, X | 2 |
| Vaccarino, A | 1 |
| Skelly, M | 2 |
| Lanzini, M | 1 |
| Hidalgo, MP | 1 |
| Soares, CN | 2 |
| Kennedy, SH | 4 |
| Frey, BN | 2 |
| Zapp, AA | 1 |
| Fischer, EC | 1 |
| Deuschle, M | 1 |
| Parry, BL | 2 |
| Meliska, CJ | 2 |
| Lopez, AM | 2 |
| Sorenson, DL | 2 |
| Martinez, LF | 2 |
| Orff, HJ | 1 |
| Hauger, RL | 2 |
| Kripke, DF | 5 |
| Slyepchenko, A | 1 |
| Minuzzi, L | 1 |
| Eltayebani, MM | 1 |
| Sassi, RB | 1 |
| Alston, M | 1 |
| Cain, SW | 3 |
| Rajaratnam, SMW | 1 |
| Forneris, CA | 1 |
| Nussbaumer-Streit, B | 1 |
| Morgan, LC | 1 |
| Greenblatt, A | 1 |
| Van Noord, MG | 1 |
| Gaynes, BN | 1 |
| Wipplinger, J | 1 |
| Lux, LJ | 1 |
| Winkler, D | 1 |
| Gartlehner, G | 1 |
| McGlashan, EM | 2 |
| Coleman, MY | 2 |
| Vidafar, P | 2 |
| Phillips, AJK | 2 |
| Stein, DJ | 1 |
| Picarel-Blanchot, F | 1 |
| Targum, SD | 3 |
| Wedel, PC | 3 |
| Robinson, J | 1 |
| Daniel, DG | 1 |
| Busner, J | 1 |
| Bleicher, LS | 2 |
| Rauh, P | 1 |
| Barlow, C | 2 |
| Sharkey, KM | 1 |
| Pearlstein, TB | 1 |
| Carskadon, MA | 1 |
| Li, SX | 1 |
| Liu, LJ | 1 |
| Xu, LZ | 1 |
| Gao, L | 1 |
| Wang, XF | 1 |
| Zhang, JT | 1 |
| Lu, L | 1 |
| Smeraldi, E | 1 |
| Delmonte, D | 1 |
| Vellante, F | 1 |
| Cornelio, M | 1 |
| Acciavatti, T | 2 |
| Cinosi, E | 1 |
| Marini, S | 1 |
| Dezi, S | 1 |
| De Risio, L | 1 |
| Di Iorio, G | 2 |
| Martinotti, G | 2 |
| Di Giannantonio, M | 2 |
| Guaiana, G | 1 |
| Gupta, S | 1 |
| Chiodo, D | 1 |
| Davies, SJ | 1 |
| Haederle, K | 1 |
| Koesters, M | 1 |
| Bouwmans, ME | 1 |
| Bos, EH | 1 |
| Booij, SH | 1 |
| van Faassen, M | 1 |
| Oldehinkel, AJ | 1 |
| de Jonge, P | 1 |
| Tarakanova, EA | 1 |
| Ivanchuk, ÉG | 1 |
| Rostovshchikov, VV | 1 |
| Mokoena, ML | 1 |
| Harvey, BH | 1 |
| Viljoen, F | 1 |
| Ellis, SM | 1 |
| Brink, CB | 1 |
| Fava, M | 2 |
| Bumb, JM | 1 |
| Enning, F | 1 |
| Mueller, JK | 1 |
| van der List, T | 1 |
| Rohleder, C | 1 |
| Findeisen, P | 1 |
| Noelte, I | 1 |
| Schwarz, E | 1 |
| Leweke, FM | 1 |
| Hamers, PC | 1 |
| Evenhuis, HM | 1 |
| Hermans, H | 1 |
| Pereira, JC | 1 |
| Pradella Hallinan, M | 1 |
| Alves, RC | 1 |
| Swanson, LM | 1 |
| Burgess, HJ | 1 |
| Huntley, ED | 1 |
| Bertram, H | 1 |
| Mooney, A | 1 |
| Zollars, J | 1 |
| Dopp, R | 1 |
| Hoffmann, R | 1 |
| Armitage, R | 1 |
| Todd Arnedt, J | 1 |
| Carvalho, LA | 2 |
| Gorenstein, C | 2 |
| Moreno, R | 1 |
| Pariante, C | 1 |
| Markus, RP | 2 |
| San, L | 1 |
| Arranz, B | 1 |
| Ergün, Y | 2 |
| Orhan, FO | 2 |
| Karaaslan, MF | 1 |
| Pandi-Perumal, SR | 3 |
| Trakht, I | 1 |
| Srinivasan, V | 3 |
| Spence, DW | 2 |
| Poeggeler, B | 1 |
| Hardeland, R | 1 |
| Cardinali, DP | 3 |
| Kochetkov, IaA | 1 |
| Nowakowski, S | 1 |
| Elliott, JA | 3 |
| Akpinar, Z | 1 |
| Tokgöz, S | 1 |
| Gökbel, H | 1 |
| Okudan, N | 1 |
| Uğuz, F | 1 |
| Yilmaz, G | 1 |
| Moscovitch, A | 1 |
| Brown, GM | 2 |
| Goodwin, GM | 1 |
| Emsley, R | 1 |
| Rembry, S | 1 |
| Rouillon, F | 1 |
| Kálmán, J | 1 |
| Kálmán, S | 1 |
| Owen, RT | 1 |
| Buckley, TM | 1 |
| Schatzberg, AF | 1 |
| Philip, NS | 1 |
| Carpenter, LL | 1 |
| Tyrka, AR | 1 |
| Price, LH | 1 |
| Serfaty, MA | 1 |
| Osborne, D | 1 |
| Buszewicz, MJ | 1 |
| Blizard, R | 1 |
| Raven, PW | 2 |
| Quera-Salva, MA | 2 |
| Lemoine, P | 1 |
| Guilleminault, C | 3 |
| de Bodinat, C | 1 |
| Guardiola-Lemaitre, B | 1 |
| Mocaër, E | 1 |
| Renard, P | 1 |
| Muñoz, C | 1 |
| Millan, MJ | 1 |
| De Berardis, D | 1 |
| Conti, C | 1 |
| Serroni, N | 1 |
| Olivieri, L | 1 |
| Cavuto, M | 1 |
| Janiri, L | 1 |
| Moschetta, FS | 1 |
| Conti, P | 1 |
| Lieverse, R | 1 |
| Van Someren, EJ | 1 |
| Nielen, MM | 1 |
| Uitdehaag, BM | 1 |
| Smit, JH | 1 |
| Hoogendijk, WJ | 1 |
| Quera Salva, MA | 1 |
| Hartley, S | 1 |
| Barbot, F | 1 |
| Alvarez, JC | 1 |
| Lofaso, F | 1 |
| Spadoni, G | 1 |
| Bedini, A | 1 |
| Rivara, S | 1 |
| Mor, M | 1 |
| Hickie, IB | 2 |
| Rogers, NL | 2 |
| Hajak, G | 1 |
| Philip, P | 1 |
| Montplaisir, J | 1 |
| Keufer-Le Gall, S | 1 |
| Laredo, J | 1 |
| Birchler-Pedross, A | 3 |
| Frey, S | 3 |
| Chellappa, SL | 1 |
| Götz, T | 3 |
| Brunner, P | 3 |
| Knoblauch, V | 3 |
| Wirz-Justice, A | 3 |
| Cajochen, C | 3 |
| Howland, RH | 1 |
| Barbui, C | 1 |
| Cipriani, A | 1 |
| Carroll, BJ | 1 |
| Jureidini, J | 1 |
| Raven, M | 1 |
| Serfaty, M | 1 |
| Lloret-Linares, C | 1 |
| Bergmann, JF | 1 |
| Mouly, S | 1 |
| Hofstetter, M | 2 |
| Münch, M | 2 |
| Blatter, K | 2 |
| Khaleghipour, S | 1 |
| Masjedi, M | 1 |
| Ahade, H | 1 |
| Enayate, M | 1 |
| Pasha, G | 1 |
| Nadery, F | 1 |
| Ahmadzade, G | 1 |
| Naismith, SL | 1 |
| Hermens, DF | 1 |
| Ip, TK | 1 |
| Bolitho, S | 1 |
| Scott, E | 1 |
| Nierenberg, AA | 1 |
| Carter, TA | 1 |
| Hen, R | 1 |
| Gage, FH | 1 |
| Llorca, PM | 1 |
| Wu, YH | 1 |
| Ursinus, J | 1 |
| Zhou, JN | 2 |
| Scheer, FA | 1 |
| Ai-Min, B | 1 |
| van Heerikhuize, J | 1 |
| Swaab, DF | 1 |
| Lôo, H | 1 |
| Hale, A | 1 |
| D'haenen, H | 1 |
| Crasson, M | 1 |
| Kjiri, S | 1 |
| Colin, A | 1 |
| Kjiri, K | 1 |
| L'Hermite-Baleriaux, M | 1 |
| Ansseau, M | 1 |
| Legros, JJ | 1 |
| Epperson, CN | 1 |
| Terman, M | 1 |
| Terman, JS | 1 |
| Hanusa, BH | 1 |
| Oren, DA | 1 |
| Peindl, KS | 1 |
| Wisner, KL | 1 |
| Loving, RT | 2 |
| Knickerbocker, NC | 2 |
| Grandner, MA | 2 |
| Fuchs, E | 1 |
| Simon, M | 1 |
| Schmelting, B | 1 |
| Moreno, RA | 1 |
| Smits, M | 1 |
| Spence, W | 1 |
| Lowe, AD | 1 |
| Kayumov, L | 1 |
| Parry, B | 1 |
| Ergün, UG | 1 |
| Küçük, E | 1 |
| Tan, ZL | 1 |
| Bao, AM | 1 |
| Zhao, GQ | 1 |
| Liu, YJ | 1 |
| Ghosh, A | 1 |
| Hellewell, JS | 1 |
| Bozhko, GKh | 1 |
| Tsaritsinskiĭ, VI | 1 |
| Kulabukhov, VM | 1 |
| Taranskaia, AD | 1 |
| Nathan, PJ | 1 |
| Burrows, GD | 1 |
| Norman, TR | 1 |
| Lewy, AJ | 1 |
| Bauer, VK | 1 |
| Cutler, NL | 1 |
| Sack, RL | 1 |
| Dalton, EJ | 1 |
| Rotondi, D | 1 |
| Levitan, RD | 1 |
| Grunhaus, L | 1 |
| Hirschman, S | 1 |
| Dolberg, OT | 1 |
| Schreiber, S | 1 |
| Dannon, PN | 1 |
| Paparrigopoulos, T | 1 |
| Psarros, C | 1 |
| Bergiannaki, JD | 1 |
| Varsou, E | 1 |
| Dafni, U | 1 |
| Stefanis, C | 1 |
| Fountoulakis, KN | 1 |
| Karamouzis, M | 1 |
| Iacovides, A | 1 |
| Nimatoudis, J | 1 |
| Diakogiannis, J | 1 |
| Kaprinis, G | 1 |
| Demitriadou, A | 1 |
| Bech, P | 1 |
| Tuunainen, A | 1 |
| Assmus, JD | 1 |
| Rex, KM | 1 |
| Klauber, MR | 1 |
| Langer, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder[NCT01942733] | Phase 3 | 44 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease[NCT03977441] | Phase 4 | 240 participants (Anticipated) | Interventional | 2019-07-31 | Not yet recruiting | ||
| Correlation Between CYP1A2, ABCB1, CYP2C9 Gene Polymorphisms and Plasma Concentration of Agomelatine and Its Metabolites in Adult Patients With Depression[NCT06120543] | 50 participants (Anticipated) | Observational | 2023-10-31 | Not yet recruiting | |||
| Circadian Health in Patients Admitted to Intensive Care Units and Hospitalization (CHRONOHOSPI)[NCT04113876] | 975 participants (Actual) | Observational [Patient Registry] | 2019-01-01 | Completed | |||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Salicylic Augmentation in Depression[NCT03152409] | Phase 2 | 74 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| The Light Heart Study: Daily Light Box Use for Depressive Symptoms in Patients With Stage B Heart Failure[NCT02691000] | 122 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | |||
| High Cortisol Levels as a Risk Factor for Depression in the Elderly and the Effect of Bright Light Treatment on Mood, Sleep-Wake Pattern and Self-Sufficiency[NCT00332670] | Phase 2/Phase 3 | 89 participants (Actual) | Interventional | 2003-01-31 | Terminated (stopped due to End of research time, time-resources) | ||
| Bright Light Therapy Efficacy for Depressive Symptoms Following Cardiac Surgery or Acute Coronary Syndrome: Pilot Trial[NCT02621567] | Phase 4 | 15 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults (ANSWERS-OA): A Pilot, Open-Label, Randomized Controlled Trial of Digital Cognitive Behavioral Therapy for Insomnia[NCT04986007] | 70 participants (Anticipated) | Interventional | 2021-09-01 | Enrolling by invitation | |||
| The Study of Morning and Nocturnal Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder[NCT01357083] | 92 participants (Anticipated) | Observational | 2010-08-31 | Completed | |||
| A Randomised, Double-blind, Placebo-controlled Study of Light Therapy for Antepartum Depression[NCT01043289] | 46 participants (Actual) | Interventional | 2004-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinical Global Impression - Global Improvement (CGI-I) assesses the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | 2.2 |
The Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) is a clinician-rated scale designed to assess biological rhythms. The BRIAN consists of 18 items divided in 4 subscales: sleep (5 items), activity (5 items), social (4 items), and eating pattern (4 items). Each item is rated on a scale from 1 (no difficulties) to 4 (serious difficulties). The total score of the 18 items ranges from 18 to 72, with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -17.4 |
The Clinical Global Impression - Severity of Illness (CGI-S) scale assesses the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients), with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -1.8 |
The Cognitive and Physical Functioning Questionnaire (CPFQ) is a patient-rated scale designed to assess cognitive and executive dysfunction including symptoms of fatigue in mood and anxiety disorders. The CPFQ consists of 7 items, each rated on a scale from 1 (greater than normal functioning) to 6 (poorer than normal functioning). The total score of the 7 items ranges from 7 to 42, with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -8.4 |
The Insomnia Severity Index (ISI) is a patient-rated scale desgined to measure the patient's perception of his/her insomnia. The ISI comprises 7 items: difficulty falling asleep, difficulty staying asleep, problems waking up early in the morning, satisfaction with current sleep pattern, interference with daily functioning, how much others notice the sleep problem impairs quality of life, and distress caused by the sleep problem. Each of the 7 items is rated on a 5-point scale from 0 (best situation) to 4 (worst situation). The total score of the 7 items ranges from 0 to 28, with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -9.2 |
The Montgomery Aasberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptoms) to 6 (severe symptoms). Definitions of severity are provided at two-point intervals. The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -16.0 |
The Bond-Lader Visual Analogue Scale - Sedation (BL-VAS-s) is a patient-rated scale designed to assess the current level of sedation. The BL-VAS-s was assessed for the evening (19:00 to 23:59 hours), morning (00:00 to 08:59 hours) and at noon (11:00 to 13:59 hours). The BL-VAS-s is a single item scale rated on a 100mm visual analogue scale. The score is measured from the left to a mark made on the line by the patient and ranges from 0 (alert) to 100 (drowsy). As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | 1.4 |
The Bond-Lader Visual Analogue Scale - Sedation (BL-VAS-s) is a patient-rated scale designed to assess the current level of sedation. The BL-VAS-s was assessed for the evening (19:00 to 23:59 hours), morning (00:00 to 08:59 hours) and at noon (11:00 to 13:59 hours). The BL-VAS-s is a single item scale rated on a 100mm visual analogue scale. The score is measured from the left to a mark made on the line by the patient and ranges from 0 (alert) to 100 (drowsy). As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -9.2 |
The Bond-Lader Visual Analogue Scale - Sedation (BL-VAS-s) is a patient-rated scale designed to assess the current level of sedation. The BL-VAS-s was assessed for the evening (19:00 to 23:59 hours), morning (00:00 to 08:59 hours) and at noon (11:00 to 13:59 hours). The BL-VAS-s is a single item scale rated on a 100mm visual analogue scale. The score is measured from the left to a mark made on the line by the patient and ranges from 0 (alert) to 100 (drowsy). As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -7.4 |
The Epworth Sleepiness Scale (ESS) is a is a patient-rated scale designed to measure daytime sleepiness. The ESS consists of 8 items describing different situations/activities and the patients rate the chance of them dozing off or falling asleep when they are in these situations. Each item is rated on a 4-point scale from 0 (would never dose) to 3 (high change of dozing). The total score of the 8 items ranges from 0 to 24, with higher values indicating worse outcome. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Brexpiprazole | -2.6 |
The psychomotor vigilance task (PVT) measures sustained or vigilant attention by recording response time (milliseconds) to a visual/or auditory stimulus that appears at random inter-stimulus intervals (range: from 2 to 10 seconds). The patient was instructed to monitor a red rectangular box on the computer screen and to press a response button as soon as a yellow stimulus counter appeared on the screen. The parameters assessed using a PVT device were response speed and number of lapses. The results for response speed is presented separately from the number of lapses due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | number (Mean) |
|---|---|
| Brexpiprazole | 2.1 |
The psychomotor vigilance task (PVT) measures sustained or vigilant attention by recording response time (milliseconds) to a visual/or auditory stimulus that appears at random inter-stimulus intervals (range: from 2 to 10 seconds). The patient was instructed to monitor a red rectangular box on the computer screen and to press a response button as soon as a yellow stimulus counter appeared on the screen. The parameters assessed using a PVT device were response speed and number of lapses. The results for response speed is presented separately from the number of lapses due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | speed (per second) (Mean) |
|---|---|
| Brexpiprazole | -0.2 |
The key ACT parameters assessed were the total sleep time (ACT TST), sleep efficiency (ACT SE), sleep onset latency (ACT SOL), wake-time after sleep onset (ACT WASO), and the number of awakenings (ACT NAW). The results for ACT TST, ACT SE, ACT WASO, and ACT NAW are presented separately from ACT SOL as the number of patients available for analysis was different. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | number of events (Mean) |
|---|---|
| Brexpiprazole | -2.0 |
The key ACT parameters assessed were the total sleep time (ACT TST), sleep efficiency (ACT SE), sleep onset latency (ACT SOL), wake-time after sleep onset (ACT WASO), and the number of awakenings (ACT NAW). The results for ACT TST, ACT SE, ACT WASO, and ACT NAW are presented separately from ACT SOL as the number of patients available for analysis was different. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | percentage of time (Mean) |
|---|---|
| Brexpiprazole | -1.3 |
The key PSG parameters assessed were the latency to persistent sleep (PSG LPS), sleep onset latency (PSG SOL), wake-time after sleep onset (PSG WASO), total sleep time (PSG TST), number of awakenings (PSG NAW), and sleep efficiency (PSG SE). The results for PSG LPS, PSG SOL, PSG WASO, and PSG TST are presented separately from the PSG NAW, and from the PSG SE due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | number of events (Mean) |
|---|---|
| Brexpiprazole | 0.06 |
The key PSG parameters assessed were the latency to persistent sleep (PSG LPS), sleep onset latency (PSG SOL), wake-time after sleep onset (PSG WASO), total sleep time (PSG TST), number of awakenings (PSG NAW), and sleep efficiency (PSG SE). The results for PSG LPS, PSG SOL, PSG WASO, and PSG TST are presented separately from the PSG NAW, and from the PSG SE due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | percentage (%) (Mean) |
|---|---|
| Brexpiprazole | 10.4 |
The key CSD-M parameters assessed were the sleep efficiency (CSD-M SE), total sleep time (CSD-M TST), sleep onset latency (CSD-M SOL), wake-time after sleep onset (CSD-M WASO), and number of awakenings (CSD-M NAW). As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | number (Mean) |
|---|---|
| Brexpiprazole | 0.0 |
The key CSD-M parameters assessed were the sleep efficiency (CSD-M SE), total sleep time (CSD-M TST), sleep onset latency (CSD-M SOL), wake-time after sleep onset (CSD-M WASO), and number of awakenings (CSD-M NAW). The results for CSD-M SE are presented separately from CSD-M TST, CSD-M SOL, and CSD-M WASO, and from CSD-M NAW due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | percentage of time (Mean) |
|---|---|
| Brexpiprazole | 13.4 |
The Montgomery Aasberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptoms) to 6 (severe symptoms). Definitions of severity are provided at two-point intervals. The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome. Remission was defined as a MADRS total score ≤10 and a ≥50% decrease in MADRS total score from baseline. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Week 8
| Intervention | percentage of patients (Number) |
|---|---|
| Brexpiprazole | 54 |
The Montgomery Aasberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptoms) to 6 (severe symptoms). Definitions of severity are provided at two-point intervals. The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome. Response was defined as a ≥50% decrease in MADRS total score from baseline. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Week 8
| Intervention | percentage of patients (Number) |
|---|---|
| Brexpiprazole | 56 |
The parameters used to assess circadian and biological rhythm were the time to peak cortisol concentration, time to dim-light melatonin onset (DLMO) and phase angle. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | minutes (Mean) | ||
|---|---|---|---|
| Time to peak cortisol concentration | Time to DLMO | Phase angle | |
| Brexpiprazole | -60 | 48 | 108 |
The key sleep architecture parameters assessed with polysomnography were the percentage of time and duration spent in Stages N1 (non-rapid eye movement [non-REM]), N2 (non-REM), N3 (non-REM), and REM, respectively, as well as the duration of latency to REM sleep. The results for the percentage of time spent at each stage is presented separately from the duration due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | percentage of total sleep duration (Mean) | |||
|---|---|---|---|---|
| Stage N1 (n=40) | Stage N2 (n=40) | Stage N3 (n=40) | Stage REM (n=40) | |
| Brexpiprazole | -0.7 | 3.5 | -2.2 | -0.6 |
The key sleep architecture parameters assessed with polysomnography were the percentage of time and duration spent in Stages N1 (non-rapid eye movement [non-REM]), N2 (non-REM), N3 (non-REM), and REM, respectively, as well as the duration of latency to REM sleep. The results for the percentage of time spent at each stage is presented separately from the duration due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | minutes (Mean) | ||||
|---|---|---|---|---|---|
| Stage N1 Duration (n=41) | Stage N2 Duration (n=41) | Stage N3 Duration (n=41) | Stage REM Duration (n=41) | Latency to REM Sleep Duration (n=38) | |
| Brexpiprazole | 4.5 | 43.1 | -3.1 | 4.5 | -16.2 |
The key ACT parameters assessed were the total sleep time (ACT TST), wake-time after sleep onset (ACT WASO), sleep onset latency (ACT SOL), sleep efficiency (ACT SE), and the number of awakenings (ACT NAW). The results for ACT TST, ACT WASO, and ACT SOL are presented separately from ACT SE, and from ACT NAW, due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | minutes (Mean) | ||
|---|---|---|---|
| ACT TST (n=33) | ACT WASO (n=33) | ACT SOL (n=32) | |
| Brexpiprazole | -9.0 | -6.1 | -5.5 |
The key PSG parameters assessed were the latency to persistent sleep (PSG LPS), sleep onset latency (PSG SOL), wake-time after sleep onset (PSG WASO), total sleep time (PSG TST), number of awakenings (PSG NAW), and sleep efficiency (PSG SE). The results for PSG LPS, PSG SOL, PSG WASO, and PSG TST are presented separately from the PSG NAW, and from the PSG SE due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | minutes (min) (Mean) | |||
|---|---|---|---|---|
| PSG LPS (n=40) | PSG SOL (n=40) | PSG WASO (n=40) | PSG TST (n=41) | |
| Brexpiprazole | -24.9 | -19.7 | -26.4 | 49.0 |
The key CSD-M parameters assessed were the sleep efficiency (CSD-M SE), total sleep time (CSD-M TST), sleep onset latency (CSD-M SOL), wake-time after sleep onset (CSD-M WASO), and number of awakenings (CSD-M NAW). The results for CSD-M SE are presented separately from CSD-M TST, CSD-M SOL, and CSD-M WASO, and from CSD-M NAW due to the different units of measurement involved. As this was an open-label exploratory study, all outcomes should be considered as exploratory outcomes. (NCT01942733)
Timeframe: Baseline and Week 8
| Intervention | minutes (min) (Mean) | ||
|---|---|---|---|
| CSD-M TST (n=21) | CSD-M SOL (n=21) | CSD-M WASO (n=21) | |
| Brexpiprazole | 69.9 | -37.1 | -42.9 |
27 reviews available for melatonin and Depressive Disorder, Major
| Article | Year |
|---|---|
The role of Neurochemicals, Stress Hormones and Immune System in the Positive Feedback Loops between Diabetes, Obesity and Depression.
Topics: Adolescent; Depression; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Feedback; Humans; Imm | 2023 |
Biological Rhythms Advance in Depressive Disorder.
Topics: Antidepressive Agents; Circadian Rhythm; Cognitive Behavioral Therapy; Depressive Disorder, Major; H | 2019 |
Evening wear of blue-blocking glasses for sleep and mood disorders: a systematic review.
Topics: Bipolar Disorder; Circadian Rhythm; Depressive Disorder, Major; Eyeglasses; Female; Humans; Light; M | 2021 |
Melatonin receptors, brain functions, and therapies.
Topics: Aged; Animals; Brain; Circadian Rhythm; Depressive Disorder, Major; Humans; Melatonin; Receptor, Mel | 2021 |
The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Design; Humans; Melatonin; Receptor | 2017 |
Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition.
Topics: Cognition; Cognitive Dysfunction; Depressive Disorder, Major; DNA Repair; Humans; Inflammation; Mela | 2018 |
Psychological therapies for preventing seasonal affective disorder.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Humans; Melatonin; | 2019 |
Agomelatine in depression.
Topics: Acetamides; Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Me | 2013 |
Treatment of resistant insomnia and major depression.
Topics: Anticonvulsants; Brain Stem; Circadian Rhythm; Complementary Therapies; Depressive Disorder, Major; | 2013 |
Agomelatine versus other antidepressive agents for major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomized | 2013 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; H | 2008 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; H | 2008 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; H | 2008 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; H | 2008 |
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
Topics: Acetamides; Affect; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Indenes; Melat | 2009 |
[Melatonin and depression].
Topics: Depressive Disorder, Major; Humans; Melatonin | 2007 |
Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Topics: Acetamides; Animals; Brain; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, Major; H | 2009 |
[Depression as chronobiological illness].
Topics: Acetamides; Affect; Biological Clocks; Chronotherapy; Circadian Rhythm; Depression; Depressive Disor | 2009 |
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; | 2009 |
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.
Topics: Acetylcholine; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Del | 2010 |
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.
Topics: Acetylcholine; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Del | 2010 |
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.
Topics: Acetylcholine; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Del | 2010 |
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.
Topics: Acetylcholine; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Del | 2010 |
Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomize | 2010 |
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drug Desig | 2010 |
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mel | 2011 |
Circadian rhythms, melatonin and depression.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Chronobiology Disorders; Depressive D | 2011 |
Melatonin receptor agonists: new options for insomnia and depression treatment.
Topics: Animals; Depressive Disorder; Depressive Disorder, Major; Drug Design; Humans; Melatonin; Receptors, | 2011 |
Novel melatonin-based therapies: potential advances in the treatment of major depression.
Topics: Acetamides; Antidepressive Agents; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, M | 2011 |
[Early effects of antidepressants].
Topics: Acetamides; Affect; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, | 2012 |
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Di | 2006 |
Melatonin in mood disorders.
Topics: Antidepressive Agents; Biomarkers; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Depressi | 2006 |
A review of the efficacy and tolerability of agomelatine in the treatment of major depression.
Topics: Acetamides; Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Melatonin | 2007 |
24 trials available for melatonin and Depressive Disorder, Major
| Article | Year |
|---|---|
Sini powder with paroxetine ameliorates major depressive disorder by modulating circadian rhythm: A randomized, double-blind, placebo-controlled trial.
Topics: Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drugs, Chinese Herbal; Humans; | 2022 |
The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Majo | 2019 |
Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial.
Topics: Adult; Aged; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Electroconvulsive Therapy | 2020 |
Early versus late wake therapy improves mood more in antepartum versus postpartum depression by differentially altering melatonin-sleep timing disturbances.
Topics: Adult; Affect; Circadian Rhythm; Depression, Postpartum; Depressive Disorder, Major; Female; Humans; | 2019 |
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; | 2013 |
A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
Topics: Analysis of Variance; Antidepressive Agents; Buspirone; Depressive Disorder, Major; Double-Blind Met | 2013 |
Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder.
Topics: Acute Disease; Antioxidants; Buspirone; Cognition Disorders; Depressive Disorder, Major; Double-Blin | 2015 |
A multicenter randomized controlled trial for bright light therapy in adults with intellectual disabilities and depression: Study protocol and obstacle management.
Topics: Actigraphy; Adult; Circadian Rhythm; Depression; Depressive Disorder, Major; Hair; Humans; Hydrocort | 2017 |
Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation.
Topics: Adult; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Female; Fluoxetine; Huma | 2017 |
Effect of antidepressants on melatonin metabolite in depressed patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti | 2009 |
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administr | 2009 |
A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.
Topics: Adult; Antidepressive Agents; Central Nervous System Depressants; Delayed-Action Preparations; Depre | 2010 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Depressive Disorder, Major; Double-Blind Method; F | 2011 |
Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Topics: Acetamides; Adult; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypn | 2011 |
An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
Topics: Adult; Animals; Behavior, Animal; Buspirone; Delayed-Action Preparations; Depressive Disorder, Major | 2012 |
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2002 |
Serum melatonin and urinary 6-sulfatoxymelatonin in major depression.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Circadian Rhythm; Depressive Disorder, Major; Female | 2004 |
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings.
Topics: Adult; Circadian Rhythm; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2004 |
Bright light treatment of depression for older adults [ISRCTN55452501].
Topics: Age Factors; Aged; Antidepressive Agents; Circadian Rhythm; Combined Modality Therapy; Depressive Di | 2005 |
Bright green light treatment of depression for older adults [ISRCTN69400161].
Topics: Adult; Age Factors; Aged; Circadian Rhythm; Clinical Protocols; Color; Depressive Disorder, Major; F | 2005 |
Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Circadian Rhythm; Depressive Disorder, Major; Femal | 2007 |
Melatonin treatment of winter depression: a pilot study.
Topics: Adult; Arousal; Circadian Rhythm; Depressive Disorder, Major; Dose-Response Relationship, Drug; Doub | 1998 |
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT.
Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relatio | 2001 |
Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction.
Topics: Adult; Clonidine; Depressive Disorder, Major; Female; Humans; Male; Melatonin; Middle Aged; Receptor | 2001 |
39 other studies available for melatonin and Depressive Disorder, Major
| Article | Year |
|---|---|
Agomelatine: An Astounding Sui-generis Antidepressant?
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Naphthalenes; Rece | 2022 |
Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation.
Topics: Animals; Astrocytes; Autophagy; Depressive Disorder, Major; Forkhead Box Protein O3; Gene Expression | 2020 |
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy.
Topics: Circadian Rhythm; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Melatonin; Quinolon | 2021 |
Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis.
Topics: Actigraphy; Adult; Bipolar Disorder; Case-Control Studies; Circadian Rhythm; Depressive Disorder, Ma | 2018 |
The effect of agomelatine and melatonin on sleep-related eating: a case report.
Topics: Acetamides; Central Nervous System Depressants; Depressive Disorder, Major; Female; Humans; Melatoni | 2017 |
Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder.
Topics: Actigraphy; Adolescent; Adult; Aged; Bipolar Disorder; Circadian Rhythm; Depressive Disorder, Major; | 2019 |
Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep and Mood.
Topics: Circadian Rhythm; Depressive Disorder, Major; Humans; Melatonin; Mood Disorders; Sleep; Sleep Initia | 2019 |
Decreased sensitivity of the circadian system to light in current, but not remitted depression.
Topics: Case-Control Studies; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Individuality; L | 2019 |
Advanced melatonin onset relative to sleep in women with unmedicated major depressive disorder.
Topics: Adolescent; Adult; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Melatonin; Sleep; S | 2019 |
Circadian phase shifts and mood across the perinatal period in women with a history of major depressive disorder: a preliminary communication.
Topics: Actigraphy; Adult; Affect; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Light; Mela | 2013 |
Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment.
Topics: Adrenocorticotropic Hormone; Adult; Case-Control Studies; Circadian Rhythm; Circadian Rhythm Signali | 2013 |
Intra- and inter-individual variability of longitudinal daytime melatonin secretion patterns in depressed and non-depressed individuals.
Topics: Adult; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Mel | 2015 |
[Problems of depressive insomnia].
Topics: Acetamides; Adult; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedat | 2014 |
Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder, Major | 2015 |
Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Circadian Rhythm; Depressive Disorder, Major; Enzyme- | 2016 |
Secondary to excessive melatonin synthesis, the consumption of tryptophan from outside the blood-brain barrier and melatonin over-signaling in the pars tuberalis may be central to the pathophysiology of winter depression.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Depressive Disorder, Major; Diet; Humans; Ligh | 2017 |
Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dose-Response Re | 2008 |
Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression.
Topics: Adult; Breast Feeding; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disor | 2008 |
The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis.
Topics: Acute Disease; Adult; Circadian Rhythm; Comorbidity; Depressive Disorder, Major; Disability Evaluati | 2008 |
A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker?
Topics: Adult; Circadian Rhythm; Cross-Sectional Studies; Depressive Disorder, Major; Female; Humans; Hydroc | 2010 |
Higher frontal EEG synchronization in young women with major depression: a marker for increased homeostatic sleep pressure?
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder, Major; Electroencephalography Phase Sy | 2011 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Novel melatonin-based treatments for major depression.
Topics: Depressive Disorder, Major; Humans; Melatonin | 2012 |
Young women with major depression live on higher homeostatic sleep pressure than healthy controls.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Circadian Rhythm; Depressive Disorder, Major; Electro | 2012 |
Challenging the sleep homeostat: sleep in depression is not premature aging.
Topics: Adult; Aged; Aging, Premature; Case-Control Studies; Depressive Disorder, Major; Electroencephalogra | 2012 |
Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study.
Topics: Adult; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Circadian Rhythm; Cross- | 2012 |
Circadian profiles in young people during the early stages of affective disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Area Under Curve; Attention; Child; Circadian Rhythm; Depressi | 2012 |
Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Case-Control Studies; Circadian Rhythm; Depressive Disord | 2013 |
Melatonin levels in drug-free patients with major depression from the southern hemisphere.
Topics: Adult; Brazil; Circadian Rhythm; Depressive Disorder, Major; Female; Geography; Humans; Male; Matche | 2006 |
Co-administration of a nitric oxide synthase inhibitor and melatonin exerts an additive antidepressant-like effect in the mouse forced swim test.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Drug Evaluation, Preclinical; Drug Syner | 2006 |
[Melatonin excretion in patients with depression under the action of light of increased intensity].
Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder, Major; Female; Fluorometr | 1995 |
Melatonin sensitivity to dim white light in affective disorders.
Topics: Adolescent; Adult; Aged; Biomarkers; Bipolar Disorder; Depressive Disorder, Major; Humans; Light; Me | 1999 |
Use of slow-release melatonin in treatment-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Re | 2000 |
Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40-41.5 degrees ).
Topics: Adult; Depressive Disorder, Major; Dexamethasone; Female; Greece; Humans; Male; Melatonin; Middle Ag | 2001 |
Depression and endogenous melatonin in postmenopausal women.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Melatonin; | 2002 |